Extracellular vesicles transport RNA between cells: Unraveling their dual role in diagnostics and therapeuticsShow others and affiliations
2024 (English)In: Molecular Aspects of Medicine, ISSN 0098-2997, E-ISSN 1872-9452, Vol. 99, article id 101302Article, review/survey (Refereed) Published
Abstract [en]
Modern methods of molecular diagnostics and therapy have revolutionized the field of medicine in recent years by providing more precise and effective tools for detecting and treating diseases. This progress includes a growing exploration of the body's secreted vesicles, known as extracellular vesicles (EVs), for both diagnostic and therapeutic purposes. EVs are a heterogeneous population of lipid bilayer vesicles secreted by almost every cell type studied so far. They are detected in body fluids and conditioned culture media from living cells. EVs play a crucial role in communication between cells and organs, both locally and over long distances. They are recognized for their ability to transport endogenous RNA and proteins between cells, including messenger RNA (mRNA), microRNA (miRNA), misfolded neurodegenerative proteins, and several other biomolecules. This review explores the dual utilization of EVs, serving not only for diagnostic purposes but also as a platform for delivering therapeutic molecules to cells and tissues. Through an exploration of their composition, biogenesis, and selective cargo packaging, we elucidate the intricate mechanisms behind RNA transport between cells via EVs, highlighting their potential use for both diagnostic and therapeutic applications. Finally, it addresses challenges and outlines prospective directions for the clinical utilization of EVs.
Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 99, article id 101302
Keywords [en]
Biomarkers, Clinical challenges, EVs, Extracellular vesicles, RNA-Based diagnosis, RNA-Based therapeutics, Surface modification, Targeted drug delivery
National Category
Cell and Molecular Biology
Research subject
Bioinformatics
Identifiers
URN: urn:nbn:se:his:diva-24421DOI: 10.1016/j.mam.2024.101302ISI: 001287351500001PubMedID: 39094449Scopus ID: 2-s2.0-85200110641OAI: oai:DiVA.org:his-24421DiVA, id: diva2:1887761
Funder
Swedish Foundation for Strategic Research, IRC15-0065Swedish Research Council, 2020-01316Knowledge Foundation, 2020-0014
Note
CC BY 4.0
Corresponding author: Hadi Valadi
E-mail address: hadi.valadi@gu.se (H. Valadi).
This work has been supported by grants from the Swedish Foundation of Strategic Research (Stiftelsen för strategisk forskning: SSF) in the Industrial Research Centre, FoRmulaEx – Nucleotide Functional Drug Delivery (Grant ID: IRC15-0065), the Swedish research council (VR, Grant ID: 2020-01316), and The Swedish Knowledge Foundation (KKS, Grant ID: 2020-0014).
2024-08-092024-08-092025-09-29Bibliographically approved